IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Howard Hoffman who wrote (1389)	12/5/1997 10:53:00 PM
From: I. Luttichuys	Read Replies (1) of 1762

Howard... the thing to watch are the CD4 cells... This has been a traditional problem with these kinds of therapies and this is why CE9.1 is out. During the earlier trials, I believe CD4 counts were relatively preserved but, in more extended trials, the counts fell and, CE9.1 was pretty much finished. I do not know exactly why this problem appeared only in subsequent trials. It may be something which was done differently during scale-up etc... hard to say but, anyway, you will notice IDEC makes it a point in the recent announcement to point out that CD4 cell populations were not disturbed. Will things stay that way... I don't know. The reason Rituxan was a non-event was because the approval was widely anticipated. No one in my circles doubted it's approval for even a minute... for over a year, at least... everyone knew it would pass. The FDA worked very closely with IDEC on this one... it's not passing would have been an embarassment. BENNETT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next